CV Lattes
ResearcherID
ORCID
Universidade de São Paulo (USP). Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP) (Institutional affiliation for the last research proposal) Birthplace: Brazil
graduation at Física São Carlos from Universidade de São Paulo (1990), master's at Física Aplicada - Sâo Carlos from Universidade de São Paulo (1993), doctorate at Chemical Biology from University of Manchester (1996) and doctorate at Física Aplicada São Carlos from Universidade de São Paulo (1997). He is currently professor doutor at Faculdade de Ciências Farmacêuticas de Ribeirão Preto-USP. Has experience in Byophysics, focusing on Byophysics, acting on the following subjects: trypanosoma cruzi, leishmania major, diidroorotato desidrogenase, cristalografia and proteínas. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
No longer than four months ago, the world was not aware of the existence of the virus SARS-CoV-2. Today, this virus, responsible for COVID-19, has already spread around the all planet, infecting more than 2 million people and killing more than 150 thousand. The pandemic caused by COVID-19 has led to the collapse of both economic and the health systems around the world. So far, social dist…
Prion diseases are progressive neurodegenerative disorders that affect both humans and animals. They are associated with the conformational conversion of the cellular prion protein PrP into PrPSc, a self-replicating isoform (prion) that accumulates in the central nervous system of affected individuals. The mechanism underlying the PrP-to-PrPSc conversion and subsequent aggregation remains…
Animal venoms constitute a rich source of pharmacologically active substances. Such molecules, named toxins, act either isolated or in synergy through the binding to cell receptors and/or interfering metabolic pathways fundamental to cell viability, inducing local, systemic and even lethal damage to the victim or pray. Exploring the mechanisms of action of toxins has been relevant for pro…
Leishmaniases are considered neglected tropical diseases due to the lack of investment from public and private sectors in the development of new methods of diagnosis and adequate therapies. Facing this tough reality, the Academy has had an important role in the identification and validation of macromolecular targets, as well as, in the search of bioactive molecules as prototypes for the d…
(Only some records are available in English at this moment)
Tuberculosis is among the ten diseases that kill the most in the world. Although treatable, resistant strains of Mycobacterium tuberculosis are becoming a serious threat to public health. In 2019 alone, for example, half a million cases of TB resistant to rifampicin (RR-TB), a drug used in combination with isoniazid, pyrazinamide and ethambutol to treat TB, were reported. Of these, 78% ar…
Although affecting more than 1 billion people and causing 35.000 deaths/day worldwide, the Neglected Tropical Diseases (NTD) are still characterized by low investment from both private and public sectors towards the development of new therapies and methods to control these ailments. Among NTDs, Cutaneous Leishmaniasis (CL) is a health problem in 85 countries, which kills 72,800 to 119,600…
According to the World Health Organization (WHO), schistosomiasis is considered a neglected parasitic disease, in other words, there is a lack of investments for the development of new and effective therapies. It is a devastating disease, affecting almost 240 million people, mostly located in the poorest portion of the world. In Brazil, schistosomiasis is caused only by the parasite Schis…
Fragment screening has emerged as an important tool in the pipeline of drug discovery. By using compounds of low molecular weight, it is possible to cover a broader range of the chemical space with fewer compounds. Fragments often bind with better ligand efficiencies than traditional screening and hits are capable of binding to a larger number of proteins than conventional 'drug-size' com…
Leishmaniasis are a group of neglected diseases that puts 350 million individuals at risk. It is caused by parasites of the genus Leishmania and transmitted by the bite of infected femalephlebotomine sandflies. There are three main forms of the disease: cutaneous, mucocutaneous and visceral. The mucocutaneous form induces deformative lesions in the nasopharyngeal and oral mucosa that in B…
The repositioning of drugs consists of the evaluation and/or use of existing drugs for treatment of diseases other than those for which they were originally developed. This strategy is of particular interest for the development of new therapeutic strategies, especially for the treatment of neglected diseases, since it allows the evaluation of bioactive potential to molecules which have ha…
(Only some records are available in English at this moment)
Prion diseases are rare neurodegenerative conditions associated with the conformational conversion of the cellular prion protein PrPC into PrPSc, a self-replicating isoform (prion) that accumulates in the central nervous system of affected individuals. The molecular mechanisms underlying the PrPC-to-PrPSc conversion and subsequent aggregation remain to be elucidated. No specific therapeut…
Leishmaniases, classified as Neglected Tropical Diseases (NTD), are caused by different species of the parasite Leishmania and affect 12 million people worldwide. Fumarate hydratase (FH) catalyzes the stereospecific reversible hydration/dehydration of fumarate to S-malate. Eukaryotes express two isoforms of FH: the mitochondrial isoform (FH-1) that is well known to participate in the tric…
The Dihydroorotate dehydrogenase enzyme has been investigated as a therapeutic target for the development of drugs with trypanocidal activity. DHODHs from trypanosomatids are attractive targets since (i) they participate in an important biochemical pathway, (ii) there are important structural differences between human and trypanosomatid enzymes (iii) trypanosomatid DHODH enzymes have diff…
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing research grants |
| 10 / 9 | Completed research grants |
| 3 / 3 | Ongoing scholarships in Brazil |
| 26 / 20 | Completed scholarships in Brazil |
| 5 / 5 | Completed scholarships abroad |
| 45 / 38 | All research grants and scholarships |
| Associated processes | |